TGF-beta - an excellent servant but a bad master

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KUBICZKOVÁ Lenka SEDLAŘÍKOVÁ Lenka HÁJEK Roman ŠEVČÍKOVÁ Sabina

Year of publication 2012
Type Article in Periodical
Magazine / Source Journal of Translational Medicine
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.translational-medicine.com/content/10/1/183
Doi http://dx.doi.org/10.1186/1479-5876-10-183
Field Oncology and hematology
Keywords TGF-beta; SMAD proteins; Oncogene; Suppressor; Solid tumors; Leukemia; Multiple myeloma
Attached files
Description The transforming growth factor (TGF-beta) family of growth factors controls an immense number of cellular responses and figures prominently in development and homeostasis of most human tissues. Work over the past decades has revealed significant insight into the TGF-beta signal transduction network, such as activation of serine/threonine receptors through ligand binding, activation of SMAD proteins through phosphorylation, regulation of target genes expression in association with DNA-binding partners and regulation of SMAD activity and degradation. Disruption of the TGF-beta pathway has been implicated in many human diseases, including solid and hematopoietic tumors. As a potent inhibitor of cell proliferation, TGF-beta acts as a tumor suppressor; however in tumor cells, TGF-beta looses anti-proliferative response and become an oncogenic factor. This article reviews current understanding of TGF-beta signaling and different mechanisms that lead to its impairment in various solid tumors and hematological malignancies.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.